Illinois Municipal Retirement Fund Purchases 264,397 Shares of Kenvue Inc. (NYSE:KVUE)

Illinois Municipal Retirement Fund grew its position in Kenvue Inc. (NYSE:KVUE) by 704.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 301,913 shares of the company’s stock after purchasing an additional 264,397 shares during the period. Illinois Municipal Retirement Fund’s holdings in Kenvue were worth $6,500,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Clearstead Advisors LLC bought a new position in Kenvue during the third quarter worth about $25,000. Planned Solutions Inc. bought a new position in shares of Kenvue during the fourth quarter worth approximately $27,000. AdvisorNet Financial Inc acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Global Retirement Partners LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 1.1 %

NYSE KVUE opened at $19.36 on Wednesday. The firm’s fifty day moving average price is $19.84 and its two-hundred day moving average price is $20.15. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 4.13%. The ex-dividend date was Tuesday, February 13th.

Analysts Set New Price Targets

A number of equities analysts have commented on KVUE shares. The Goldman Sachs Group assumed coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Royal Bank of Canada decreased their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein assumed coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Finally, William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.